Second IMI call
Brussels – The Innovative Medicines Initiative (IMI) has published its second call for funding. “By accelerating and optimising R&D processes, we are trying to remove bottlenecks in the drug development process,” explained Arthur Higgins, president of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The umbrella organisation’s member companies are participating in the research initiative together with the European Commission, which will support applicants with EUR76.8m of funding in this round. EFPIA’s Public Private Partnership with the Commission is aimed at speeding up the discovery and development of new medicines in the field of cancer, inflammatory and infectious disease. Detailed descriptions of the topics to be funded are available at imi.europa.eu/calls-02_en.html.